Oral Drug Delivery Videos

  1. Charting The Waters Of Drug Delivery Innovation With Suttons Creek 7/11/2025

    In this episode of In Combination, the technical leadership team from device consultancy Suttons Creek joins host Tom von Gunden to discuss trends in the patient landscape driving innovation in drug delivery, including combination products and therapies. The conversation covers patient self-administration, emerging modalities, and key considerations in product development, regulatory pathways, and the supply chain.

  2. Oral Drug Delivery For Breast Cancer Prevention With Atossa Therapeutics' Steven Quay 4/7/2025

    In this episode of Sit and Deliver, host Tom von Gunden talks with Atossa Therapeutics CEO Steven Quay about oral drug delivery for early intervention in patients at high risk of breast cancer. The discussion covers formulations, coatings, and dosing for orally administered, cancer-preventative approaches to reducing breast density. 

  3. Patient Safety Through Overdose Protection With Elysium Therapeutics' Greg Sturmer 11/18/2024

    Drug overdoses can result both from knowingly risky behavior, such as opioid use disorder, and from unwitting patient acts of over-consumption. In this episode of Sit and Deliver, Greg Sturmer, co-founder and CEO of biopharmaceutical company Elysium Therapeutics, talks with Sit and Deliver host Tom von Gunden about ways to add overdose inhibitors to oral medications prone to abuse or misuse.

  4. What's In A Combination Product Development Lifecycle? 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, lays out the phases and key activities in the development of a combination product or combination therapy. She underscores the importance of integrated development when merging medicinal product development with delivery device development. 

  5. Drug Delivery Market Success: Lessons From A Discontinued Product 5/23/2025

    In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, host Fran DeGrazio and James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, ponder the discontinuation of Repatha® Pushtronex®. They comment on how its withdrawal may illustrate key market drivers and factors that bolster a product’s success or, alternatively, lead to its demise.

  6. Diffucaps Technology 8/29/2024

    Discover how Diffucaps technology offers precise drug release, tailored dosage, and enhanced solubility, while minimizing irritation.

  7. Advances In Oral GLP-1 Analogs For Obesity 9/12/2024

    Discover how these groundbreaking Oral GLP-1 Analogs therapies are reshaping obesity management and addressing key challenges in formulation and delivery.

  8. The Steps In Identifying An EDDO 4/23/2025

    What constitutes an EDDO (Essential Drug Delivery Output)? In this segment of the Drug Delivery Leader Live event EDDOs Revisited: Putting Essential Drug Delivery Outputs Into Practice, consultant Susan Neadle of Combination Products Consulting Services, LLC illustrates how to identify system-level drug delivery outputs that are device-dependent and, therefore, essential. 

  9. Rapid, Material-Sparing Feasibility Screening For Hot Melt Extrusion

    Discover a screening process to quickly assess HME feasibility that yields more accurate predictions for API loading and degradation while saving material and time compared to traditional approaches.

  10. Global Harmonization Of Combination Products Regulatory 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks the panel to comment on regulatory movements of note. From his combination products and global operations leadership roles at FDA and now as regulatory consultant, panelist Barr Weiner points to global harmonization of regulatory definitions and requirements. Panelists Rumi Young and Fran DeGrazio weigh in on stability testing and specific ICH, ISO, and AAMI standards.